نتائج البحث - Tara M. Robinson

تنقيح النتائج
  1. 1
    QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC

    QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC حسب Luís Loureiro, Joshua Henshaw, S Agarwal, Andreas Tiede, Tara M. Robinson

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Specific Immune Induction Following DNA-Based Immunization Through In Vivo Transfection and Activation of Macrophages/Antigen-Presenting Cells

    Specific Immune Induction Following DNA-Based Immunization Through In Vivo Transfection and Activation of Macrophages/Antigen-Presenting Cells حسب Michael A. Chattergoon, Tara M. Robinson, Jean Boyer, David B. Weiner

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide

    Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide حسب Tara M. Robinson, Paul V. O’Donnell, Ephraim J. Fuchs, Leo Luznik

    منشور في 2016
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Functional Macroautophagy Induction by Influenza A Virus without a Contribution to Major Histocompatibility Complex Class II-Restricted Presentation

    Functional Macroautophagy Induction by Influenza A Virus without a Contribution to Major Histocompatibility Complex Class II-Restricted Presentation حسب Joseph D. Comber, Tara M. Robinson, Nicholas A. Siciliano, Adam E. Snook, Laurence C. Eisenlohr

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3′ UTR

    Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3′ UTR حسب Elliot Goodenough, Tara M. Robinson, Matthew B. Zook, Kevin M. Flanigan, John F. Atkins, Michael Howard, Laurence C. Eisenlohr

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A

    Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A حسب Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Priyanka Raheja, Carolyn M. Millar, Dane Osmond, Mingjin Li, Tara M. Robinson

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

    Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A حسب John Pasi, Michael Laffan, Savita Rangarajan, Tara M. Robinson, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Xinqun Yang, Benjamin Kim, Glenn F. Pierce, Wing Yen Wong

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity

    A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity حسب S. Hayley, Bibhav Poudel, Evanthia T. Roussos Torres, John-William Sidhom, Tara M. Robinson, Brian J. Christmas, Blake Scott, Kayla Cruz, Skylar Woolman, Valerie Wall, Todd D. Armstrong, Elizabeth M. Jaffee

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A

    Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A حسب Johannes Oldenburg, Hérvè Chambost, Hai Liu, Charles R. Hawes, Xiaojun You, Xinqun Yang, Vanessa Newman, Tara M. Robinson, Anthony J. Hatswell, David Hinds, Sandra Santos‐Martínez, Margareth C. Ozelo

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Plain language summary of 4-year results of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A

    Plain language summary of 4-year results of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A حسب Bella Madan, Margareth C. Ozelo, Gili Kenet, Sheng‐Chieh Chou, Ebony Dashiell-Aje, Tara M. Robinson, Johnny Mahlangu, Michael Recht, Francisco P. Careta, Andres Ruiz, Simon Fletcher, Dor Goshen

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Plain language summary of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A

    Plain language summary of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A حسب Gillian Lowe, Simon Fletcher, Patrick James Lynch, Johnny Mahlangu, Margareth C. Ozelo, Luke Pembroke, Steven W. Pipe, Gabriela G Yamaguti-Hayakawa, Deon York, Tara M. Robinson, Hua Yu, Leonard A. Valentino

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment

    Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment حسب Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Priyanka Raheja, Tara M. Robinson, Dane Osmond, Chris B. Russell, Christian Vettermann, Suresh Agarwal, Mingjin Li, Wing Yen Wong, Michael Laffan

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A

    Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A حسب Brian R Long, Tara M. Robinson, Jonathan R S Day, Hua Yu, Kelly Lau, Urooj Imtiaz, Kathryn Patton, Greg de Hart, Joshua Henshaw, Suresh Agarwal, Christian Vettermann, Stephen J. Zoog, Soumi Gupta

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques

    Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques حسب Rabih Halwani, Jean Boyer, Bader Yassine‐Diab, Elias K. Haddad, Tara M. Robinson, Sanjeev Kumar, Rose Parkinson, Ling Wu, Maninder K. Sidhu, Rebecca Phillipson-Weiner, George N. Pavlakis, Barbara K. Felber, Mark G. Lewis, Anding Shen, Robert F. Siliciano, David B. Weiner, Rafick‐Pierre Sékaly

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

    Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid حسب Jean Boyer, Tara M. Robinson, Michele A. Kutzler, Gordon Vansant, David A. Hokey, Sanjeev Kumar, Rose Parkinson, Ling Wu, Maninder K. Sidhu, George N. Pavlakis, Barbara K. Felber, Charles R. Brown, Peter Silvera, Mark G. Lewis, Joseph Monforte, Thomas A. Waldmann, John H. Eldridge, David B. Weiner

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1

    OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1 حسب Johnny Mahlangu, Annette von Drygalski, Susan Shapiro, Sheng‐Chieh Chou, Margareth C. Ozelo, Gili Kenet, Flora Peyvandi, B. Madan, Michael Laffan, Amy L. Dunn, Jane Mason, Doris Quon, Azita Leavitt, Johannes Oldenburg, Hérvè Chambost, Mark T. Reding, Kala Jayaram, Hua Yu, Tara M. Robinson, Steven W. Pipe

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help

    Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help حسب Michele A. Kutzler, Tara M. Robinson, Michael A. Chattergoon, Daniel Choo, Andrew Y. Choo, Philip Y. Choe, Mathura P. Ramanathan, Rose Parkinson, Sagar B. Kudchodkar, Yutaka Tamura, Maninder K. Sidhu, Vidia Roopchand, J. Joseph Kim, George N. Pavlakis, Barbara K. Felber, Thomas A. Waldmann, Jean Boyer, David B. Weiner

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

    A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure حسب Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David A. Rizzieri, Mark G. Frattini, Yair Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

    Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production حسب Jing Du, Katelyn Paz, Ryan Flynn, Ante Vulic, Tara M. Robinson, Katie E. Lineburg, Kylie A. Alexander, Jingjing Meng, Sabita Roy, Angela Panoskaltsis‐Mortari, Michaël Loschi, Geoffrey R. Hill, Jonathan S. Serody, Ivan Maillard, David B. Miklos, John Koreth, Corey Cutler, Joseph H. Antin, Jerome Ritz, Kelli P. A. MacDonald, Timothy W. Schacker, Leo Luznik, Bruce R. Blazar

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

    Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? حسب Tara M. Robinson, Ephraim J. Fuchs, Mei‐Jie Zhang, Andrew St. Martin, Myriam Labopin, Daniel A. Keesler, Didier Blaise, Asad Bashey, Jean Bourhis, Fabio Ciceri, Stefan O. Ciurea, Steven M. Devine, Mohamad Mohty, Shannon R. McCurdy, Nöel Milpied, Ian McNiece, Vanderson Rocha, Rizwan Romee, Gèrard Socié, Ibrahim Yakoub‐Agha, Robert J. Soiffer, Mary Eapen, Arnon Nagler

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: